4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4- dichlorophenyl)pyrazolo[1,5-α]-1,3,5-triazine: A potent, orally bioavailable CRF1 receptor antagonist

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 449-456

  He, Liqi ^a   Gilligan, Paul J ^a   Zaczek, Robert ^a   Fitzgerald, Lawrence W ^a   McElroy, John ^a   Shen, H S L ^a   Saye, Jo Anne ^a   Kalin, Ned H ^a,b   Shelton, Steven ^a,b   Christ, David ^a   Trainor, George ^a   Hartig, Paul ^a  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; TRIAZENE DERIVATIVE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; NONHUMAN; RAT; STEREOTYPY; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; CARDIOVASCULAR SYSTEM; DOGS; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; KIDNEY FUNCTION TESTS; MACACA MULATTA; MALE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RESPIRATORY PHYSIOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 18344405707     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9904351     Document Type: Article

References (45)

1. Rivier, J.; Spiess, J.; Vale, W. Characterization of rat hypothalamus corticotropin releasing factor. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4851-4855.
2. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213, 1394-1397.
3. 1 Antagonists. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: San Diego, CA, 1997; Vol. 32, pp 41-50.
4. Sawchenko, P. E.; Swanson, L. W. Organization of CRF immunoreactive cells and fibers in the rat brain: Immunohistochemical studies. In Corticotropin-releasing factor: basic and clinical studies of a neuropeptide; Desouza, E. B., Nemeroff, C. B., Eds.; CRC Press: Boca Raton, FL, 1990; pp 29-51.
5. Koob, G. F.; Heinrichs, S. C.; Pich, E. M.; Menzaghi, F.; Baldwin, H. Miczek, K.; Britton, K. T. The role of corticotropin releasing factor in behavioural responses to stress. In Corticotropin-releasing factor, Ciba Foundation Symposium 172; Chadwick, D. J., Marsh, J., Ackrill, K., Eds.; J. Wiley and Sons: Chicester, U.K., 1993; pp 277-291.
6. De Souza, E. B.; Insel, T. R.; Perrin, M. H.; Rivier, J. Vale, W. W.; Kuhar, M. J. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J. Neurosci. 1985, 5, 3189-3203.
7. Webster, E. L.; Torpy, D. J.; Elenkov, I. J.; Chrousos, G. P. Corticotropin-releasing hormone and inflammation. Ann. N. Y. Acad. Sci. 1998, 840, 21-32.
8. Chrousos, G. P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995, 332, 1351-1362.
9. DeSouza, E. B.; Grigoriadis, D. E. Corticotropin-Releasing Factor. Physiology, Pharmacology and Role in Central Nervous System and Immune Disorders. In Psychopharmacology; The Fourth Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven Press: New York, NY, 1995; pp 505-517.
10. DeSouza, E. B.; Bisette, G.; Whitehouse, P. J.; Powers, R. E.; Price, D. L.; Vale, W. W.; Nemeroff, C. B. Abnormalities in corticotropin releasing factor (CRF) in neurodegenerative diseases. In Corticotropin-releasing factor: basic and clinical studies of a neuropeptide; Desouza, E. B., Nemeroff, C. B., Eds.; CRC Press: Boca Raton, FL, 1990; pp 335-350.
11. Owens, M. J.; Nemeroff, C. B. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. In Corticotropin-releasing factor, Ciba Foundation Symposium 172; Chadwick, D. J., Marsh, J., Ackrill, K., Eds.; J. Wiley and Sons: Chicester, U.K., 1993; pp 296-316.
12. Banki, C. M.; Bisette, G.; Arato, M.; O'Connor, L.; Nemeroff, C. B. CSF Corticotropin-releasing Factor-like Immunoreactivity in Depression and Schizophrenia. Am. J. Psychiatry 1987, 144, 873-877.
13. France, R. D.; Urban, B.; Krishnan, R. R.; Bissette, G.; Banki, C. M.; Nemeroff, C. B.; Spielman, F. J. CSF corticotropin-releasing factor-like immunoreactivity in chronic pain patients with and without major depression. Biol. Psychiatry 1988, 23, 86-88.
14. Arato, M.; Banki, C. M.; Bissette, G.; Nemeroff, C. B. Elevated CSF CRF in suicide victims. Biol. Psychiatry 1989, 25, 355-359.
15. Raadsheer, F. C.; Hoogendijk, W. J. G.; Stam, F. C.; Tilders, F. J. H.; Swaab, D. F. Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed Patients. Neuroendocrinology 1994, 60, 436-444.
16. Gold, P. W.; Chrousos, G.; Kellner, C.; Post, R.; Roy, A.; Augerinos, P.; Schultz, H.; Oldfield, E.; Loriaux, D. L. Psychiatric implications of basic and clinical studies with corticotropin releasing factor. Am. J. Psychiatry 1984, 141, 619-627.
17. Holsboer, F.; Muller, O. A.; Doerr, H. G. ACTH and multisteroid responses to corticotropin releasing factor in depressive illness: relationship to multisteroid responses after ACTH stimulation and dexamethasone suppression. Psychoneuroendocrinology 1984, 9, 147-160.
18. Gold, P. W.; Loriaux, D. L.; Roy, A.; Kling, M. A.; Calkabrese, J. R.; Kellner, C. H.; Nieman, L. K.; Post, R. M.; Pickar, D.; Gallucci, W.; Augerinos, P.; Paul, S.; Oldfiled, E. H.; Cutler, G. B.; Chrousos, G. P. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. N. Engl. J. Med. 1986, 314, 1329-1335.
19. Sapolsky, R. M. Hypercortisolism among socially subordinate wild baboons originates at the CNS level. Arch. Gen. Psychiatry 1989, 46, 1047-1051.
20. Britton, D. R.; Koob, G. F.; Rivier, J.; Vale, W. Intracerebroventricular corticotropin releasing factor enhances behavioral effects of novelty. Life Sci. 1982, 31, 363-376.
21. Berridge, C. W.; Dunn, A. J. Corticotropin-releasing factor elicits naloxone-sensitive stress-like alterations in exploratory behavior in mice. Regul. Pept. 1986, 16, 83-93.
22. Berridge, C. W.; Dunn, A. J. A corticotropin-releasing factor antagonist reverses the stress-induced changes in exploratory behavior in mice. Horm. Behav. 1987, 21, 393-401.
23. Berridge, C. W.; Dunn, A. J. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or distress responses. Brain Res. Rev. 1990, 15, 71-100.
24. Britton, K. T.; Morgan, J.; Rivier, J.; Vale, W.; Koob, G. F. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology 1985, 86, 170-174.
25. Britton, K. T.; Lee, G.; Koob, G. F. Corticotropin-releasing factor and amphetamine exaggerate partial agonist properties of the benzodiazepine antagonist Ro 15-1788 in the conflict test. Psychopharmacology 1988, 94, 306-311.
26. Swerdlow, N. R.; Geyer, M. A.; Vale, W. W.; Koob, G. F. Corticotropin releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 1986, 88, 147-152.
27. Timpl, P.; Spanagel, R.; Sillaber, I.; Kresse, A.; Reul, J. M. H. M.; Stalla, G. K.; Blanquet, V.; Steckler, T.; Holsboer, F.; Wurst, W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genetics 1998, 19, 162-166.
28. 2γ receptor. Mol. Endocrinol. 1998, 12, 1077-1085.
29. 1 Receptor Antagonist. J. Med. Chem. 1997, 40, 1749-1754.
30. Schulz, D. W.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins. J.; Corman, M.; Dunaiskis, A.; Faraci, S.; Schmidt, A. W.; Seeger, T.; Seymour, P.; Tingley, F. D.; Winston, E. N.; Chen, Y. L.; Heym, J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10477-10482.
31. 1 receptor antagonist. Eur. J. Pharmacol 1997, 323, 21-26.
32. Griebel, G.; Perrault, G.; Sanger, D. J. Characterization of the behavioral profile of the non-peptide CRF antagonist CP154,526 in anxiety models in rodents: Comparison with diazepam and buspirone. Psychopharmacology 1998, 138, 55-66.
33. Guanowsky, V.; Chen, Y. L.; Seymour, P. A. Anxiolytic effect of the CRF antagonist, CP154526, in a light/dark anxiety test in mice. Soc. Neurosci. Abstr. 1997, 23, 203.7.
34. Arvanitis, A. G.; Gilligan, P. J.; Chorvat, R. J.; Cheeseman, R. S.; Christos, T. E.; Bakthavatchalam, R.; Beck, J. P.; Cocuzza, A. J.; Hobbs, F. W.; Wilde, R. G.; Arnold, C.; Chidester, D.; Curry, M. He, L.; Hollis, A.; Klaczltiewicz, J.; Krenitsky, P. J.; Rescinito, J. P.; Scholfield, E.; Culp, S.; De Souza, E. B.; Fitzgerald, L.; Grigoriadis, D.; Tam, S. W.; Wong, Y. N.; Huang, S.-M.; Shen, H. Non-Peptide Corticotropin-Releasing Hormone (CRH) Antagonists: The Syntheses and Structure-Activity Relationships of 2-AnilinoPyrimidinea and -Triazines. J. Med. Chem. 1999, 42, 808-818.
35. Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Arvanitis, A.; Chorvat, R. J.; Cheeseman, R. S.; Christos, T. E.; Scholfield, E.; Krenitsky, P.; Gilligan, P. J.; Ciganek, E.; Strucely, P. CRH Antagonists. II. New Framework Design and Synthesis Guided by Anilinopyrimidine Conformational Studies. J. Med. Chem. 1999, 42, 819-832.
36. Chorvat, R. J.; Bakthavatchalam, R.; Beck, J. P.; Gilligan, P. J.; Wilde, R. G.; Cocuzza, A.; Hobbs, F. W.; Cheeseman, R. S.; Curry, M.; Rescinito, J. P.; Krenitsky, P.; Chidester, D.; Yarem, J.; Klackewicz, J. D.; Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Zaczek, R.; Fitzgerald, L.; Huang, S,-M.; Shen, H. L.; Wong, Y. N.; Chien, B. M.; Quon, C. Y.; Arvanitis, A. Synthesis, Corticotropin Releasing Factor Receptor Binding Affinity and Pharmacokinetic Properties of Triazolo-, Imidazo-and Pyrrolo-Pyrimidines and Pyridines. J. Med. Chem. 1999, 42, 833-848.
37. Courtmanche, G.; Gautier, C.; Gully, D.; Roger, P.; Valette, G.; Wermuth, C.-G. Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them. U.S. Patent 5464847, 1995.
38. Structures were minimized using the PCSpartan Pro software package (v. 1.0.1; Wavefunction Inc., Irvine, CA) and superimposed such that the pendant phenyl rings were coincident.
39. He, L.; Gilligan, P. J.; Fitzgerald, L.; Zaczek, R.; Shen, H.; Trainor, G. L.; Hartig, P. R. Pyrazolo-[1,5-a]-s-triazines as novel hCRF1 receptor antagonists: Design, synthesis and structure activity relationships. American Chemical Society National Meeting, Anaheim, CA, Mar 21-25, 1999; Abstr. MEDI 107.
40. He, L.; Gilligan, P. J.; Zaczek, R.; Fitzgerald, L.; Kalin, N.; McElroy, J.; Saye, J.; Shen, H.; Shelton, S.; Smith, M.; Trainor, G.; Hartig, P. DMP696: A potent orally bioavailable pyrazolo-[1,5-a]-s-triazine corticotropin releasing factor (CRF) antagonist. American Chemical Society National Meeting, Anaheim, CA, Mar 21-25, 1999; Abstr. MEDI 4.
41. Takahashi, L. K.; Kalin, N. H.; VandenBurgt, J. A.; Sherman, J. E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. 1989, 103, 648-654.
42. 1 antagonists: Identification and pharmacological characterization. American Neuroendocrine Society, Neuroendocrine Workshop on Stress, New Orleans, LA, June 21-23, 1998; Abstr. 6.
43. Kalin, N. H.; Shelton, S. E.; Turner, J. G. Effects of alprazolam on fear-related behavioral, hormonal, and catecholamine responses in infant rhesus monkeys. Life Sci. 1991, 49, 2031-2044.
44. Perrin, D.; Armarego, W. L. F. Purification of Laboratory Chemicals, 3rd ed.; Pergamon Press: New York, NY, 1988.
45. Battaglia, G.; Webster, E. L.; De Souza, E. B. Characterization of Corticotropin-Releasing Factor Receptor-mediated Adenylate Cyclase Activity in the Rat Central Nervous System. Synapse 1987, 1, 572-581.